A Phase 4 interventional study of Alirocumab and Statins in Dyslipidemia, sponsored by Sanofi. Completed at 119 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-01.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.
Among the 349 studies in Dyslipidemias with a site in United States, this one is the 62nd largest by enrollment of the 316 interventional ones that give a count, is one of 16 that started in 2016, is one of 23 in phase 4, and was the 211th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Connecticut · Sites in United States
Ages 18–64
University of Georgia · Sites in United States
Ages 25–75 · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 76 · Phase 4 23
First in 1976; this study’s year is marked. 16 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 105 across the 316 interventional studies, 140 across the 31 observational. Of the 299 that completed or were terminated, 125 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 349 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 7 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyslipidemias with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
| NCT06382298University of GeorgiaCottonseed Oil Versus Matched PUFA Effects | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 349 studies in Dyslipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at high cardiovascular risk with non-HDL-C not adequately controlled with maximally tolerated statin therapy.
Secondary Objectives:
The maximum study duration was approximately 9 months per participant, including a 6 month treatment period, a screening period of up to 3 weeks, and an 8 week safety observation period.
For the purpose of scientific communication, a first-step analysis (both efficacy and safety) was performed at the Week 24 cut-off date. A second-step analysis was performed once all participants had completed the study to include a final update of the safety analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels \>=100 mg/dL (2.59 mmol/L) at Week 8.
Drug: Alirocumab · Drug: Statins · Drug: Antihyperglycemic Drug
Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
Drug: Statins · Drug: Ezetimibe · Drug: Fenofibrate · Drug: Nicotinic acid · Drug: Omega-3 fatty acids · Drug: Antihyperglycemic Drug
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Also known as: SAR236553, REGN727, Praluent
Statins at stable dose without other LMT as clinically indicated.
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis
Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis
LDL-C particle number was calculated from lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
LDL-C particle number was calculated from lipid subfractions by NMR spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
Time frame: From Baseline to Week 24
Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis
Absolute change = HbA1c value at specified week minus HbA1c value at baseline.
Time frame: Baseline, Week 12 and 24
Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis
Absolute change = FPG value at specified week minus FPG value at baseline.
Time frame: Baseline, Week 12 and 24
Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis
Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified week minus baseline value.
Time frame: Baseline, Week 12 and 24
The study was conducted at 119 centers in 15 countries. A total of 864 participants were screened between March 2016 and September 2016, 451 of whom were screen failures. Screen failures were mainly due to inclusion criteria not met.
| Milestone | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Started | 276 | 137 |
| Treated (safety population) | 275 | 137 |
| Itt population | 273 | 136 |
| Itt: intent to prescribe fenofibrate | 47 | 24 |
| Completed | 245 | 129 |
| Not completed | 31 | 8 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Adverse event | 10 | 4 |
| Withdrew: Withdrawal by subject | 9 | 1 |
| Withdrew: Poor compliance to study protocol | 1 | 0 |
| Withdrew: Other than specified above | 10 | 3 |
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis | -37.3 ± 3.0 | -4.7 ± 3.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -41.7 ± 3.4 | -8.5 ± 4.8 |
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis | -43.3 ± 3.6 | -0.3 ± 4.0 |
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -47.0 ± 4.2 | 8.7 ± 5.8 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis | -35.5 ± 2.9 | -9.4 ± 3.2 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum | -34.7 ± 3.2 | -7.3 ± 4.5 |
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis | -41.7 ± 3.3 | -7.0 ± 3.6 |
Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum | -44.3 ± 3.6 | 5.4 ± 5.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis | -33.8 ± 2.7 | -1.6 ± 3.0 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -38.9 ± 3.1 | -3.8 ± 4.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis | -27.4 ± 2.3 | -2.8 ± 2.5 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -30.9 ± 2.6 | -5.7 ± 3.7 |
Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were included in the imputation model.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis | -23.7 ± 1.9 | 3.7 ± 2.6 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -18.9 ± 4.4 | 3.9 ± 6.6 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis | -13.0 ± 2.0 | -8.8 ± 2.8 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -15.4 ± 4.7 | -24.4 ± 6.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis | 14.5 ± 2.5 | 8.2 ± 2.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | 13.5 ± 2.9 | 12.3 ± 4.1 |
LDL-C particle number was calculated from lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis | -41.6 ± 3.0 | -3.9 ± 3.4 |
LDL-C particle number was calculated from lipid subfractions by NMR spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate.
| Percent change | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care: Intent to Prescribe Fenofibrate |
|---|---|---|
| Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum | -45.4 ± 3.5 | -2.9 ± 5.0 |
Absolute change = HbA1c value at specified week minus HbA1c value at baseline.
| mmol/mol | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Change at Week 12 | 0.59 ± 6.82 | 0.43 ± 5.70 |
| Change at Week 24 | 2.84 ± 8.04 | 2.40 ± 8.19 |
Absolute change = FPG value at specified week minus FPG value at baseline.
| mmol/L | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Change at Week 12 | 0.45 ± 2.43 | 0.21 ± 1.86 |
| Change at Week 24 | 0.68 ± 2.54 | 0.03 ± 2.54 |
Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified week minus baseline value.
| Glucose lowering treatments | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Change at Week 12 | 0.04 ± 0.30 | 0.04 ± 0.19 |
| Change at Week 24 | 0.07 ± 0.37 | 0.04 ± 0.23 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 1/275 (0.4%) | 26/275 (9.5%) | 37/275 (13.5%) |
| Usual Care | 0/137 (0%) | 12/137 (8.8%) | 27/137 (19.7%) |
| Event | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| Ischaemic strokeNervous system disorders | 2/275 | 2/137 |
| Angina unstableCardiac disorders | 3/275 | 0/137 |
| Acute myocardial infarctionCardiac disorders | 1/275 | 1/137 |
| Cholecystitis acuteHepatobiliary disorders | 0/275 | 1/137 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/275 | 1/137 |
| Back painMusculoskeletal and connective tissue disorders | 0/275 | 1/137 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/275 | 1/137 |
| Cerebrovascular accidentNervous system disorders | 0/275 | 1/137 |
| DizzinessNervous system disorders | 0/275 | 1/137 |
| Facial paralysisNervous system disorders | 0/275 | 1/137 |
| Event | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/275 | 9/137 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/275 | 8/137 |
| Urinary tract infectionInfections and infestations | 15/275 | 5/137 |
| BronchitisInfections and infestations | 5/275 | 7/137 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| Mean | 62.8 ± 9.3 | 64.1 ± 8.8 | 63.2 ± 9.2 |
| Sex: Female, Male(Participants) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| Female | 129 | 68 | 197 |
| Male | 147 | 69 | 216 |
| Ethnicity (NIH/OMB)(Participants) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| Hispanic or Latino | 35 | 14 | 49 |
| Not Hispanic or Latino | 240 | 123 | 363 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| White/Caucasian | 247 | 123 | 370 |
| Black | 16 | 6 | 22 |
| Asian/Oriental | 3 | 7 | 10 |
| American Indian or Alaska Native | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 6 | 1 | 7 |
| Non-HDL-C(mg/dL) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| Mean | 155.1 ± 46.2 | 161.5 ± 48.8 | 157.2 ± 47.1 |
| Non-HDL-C(mmol/L) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| Mean | 4.0 ± 1.2 | 4.2 ± 1.2 | 4.073 ± 1.221 |
| Intent to Prescribe Treatment(Participants) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Usual Care | Total |
|---|---|---|---|
| Fenofibrate | 48 | 24 | 72 |
| No additional LMT | 79 | 39 | 118 |
| Ezetimibe | 104 | 52 | 156 |
| Omega-3 fatty acids | 43 | 21 | 64 |
| Nicotinic acid | 2 | 1 | 3 |
Showing the first 100 of 119 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2016, a primary completion of Mar 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab